Abstract:Fungal infections are incurring high risks in a range from superficial mucosal discomforts (such as oropharyngeal candidiasis and vulvovaginal candidiasis) to disseminated life-threatening diseases (such as invasive pulmonary aspergillosis and cryptococcal meningitis) and becoming a global health problem in especially immunodeficient population. The major obstacle to conquer fungal harassment lies in the presence of increasing resistance to conventional antifungal agents used in newly clinically isolated strains. Although recombinant cytokines and mono-/poly-clonal antibodies are added into antifungal armamentarium, more effective antimycotic drugs are exceedingly demanded. It is comforting that the development of fungal vaccines and adjuvants opens up a window to brighten the prospective way in the diagnosis, prevention and treatment of fungal assaults. In this review, we focus on the progression of several major fungal vaccines devised for the control of Candida spp., Aspergillus spp., Cryptococcus spp., Coccidioides spp., Paracoccidioides spp., Blastomyces spp., Histoplasma spp., Pneumocystis spp. as well as the adjuvants adopted. We then expound the interaction between fungal vaccines/adjuvants and host innate (macrophages, dendritic cells, neutrophils), humoral (IgG, IgM and IgA) and cellular (Th1, Th2, Th17 and Tc17) immune responses which generally experience immune recognition of pattern recognition receptors, activation of immune cells, and clearance of invaded fungi. Furthermore, we anticipate an in-depth understanding of immunomodulatory properties of univalent and multivalent vaccines against diverse opportunistic fungi, providing helpful information in the design of novel fungal vaccines and adjuvants.

Antigenic peptide-tobacco mosaic virus conjugates as a fungal vaccine candidate

Genetically Engineered Virus Nanofibers As an Efficient Vaccine for Preventing Fungal Infection

Vaccine Against Fungal Infections: Genetically Engineered Virus Nanofibers as an Efficient Vaccine for Preventing Fungal Infection (Adv. Healthcare Mater. 7/2016).

Development of Tobacco necrosis virus A as a vector for efficient and stable expression of FMDV VP1 peptides.

Immunity and Protective Efficacy of a Plant-Based Tobacco Mosaic Virus-like Nanoparticle Vaccine against Influenza a Virus in Mice

Study on Fungal Fermentation Broth and Resistance Substance of Anti-Tobacco Mosaic Virus

A Novel Mucosal Vaccine Against Foot-and-Mouth Disease Virus Induces Protection in Mice and Swine

Efficient production of antifungal proteins in plants using a new transient expression vector derived from tobacco mosaic virus

Synthesis and immunological studies of β-1,2-mannan-peptide conjugates as antifungal vaccines.

Synthesis and Immunological Evaluation of Disaccharide Bearing MUC-1 Glycopeptide Conjugates with Virus-like Particles

Transcutaneous Immunization of 1D Rod-Like Tobacco-Mosaic-Virus-Based Peptide Vaccine via Tip-Loaded Dissolving Microneedles

Fungal vaccines and adjuvants: a tool to reveal the interaction between host and fungi

Inhibitory effect of polysaccharide peptide (PSP) against Tobacco mosaic virus (TMV)

Trifluoromethylpyridine Thiourea Derivatives: Design, Synthesis and Inhibition of the Self-Assembly of Tobacco Mosaic Virus Particles

Immunogenicity of the Epitope of the Foot-and-Mouth Disease Virus Fused with a Hepatitis B Core Protein As Expressed in Transgenic Tobacco

Oral immunogenicity of potato-derived antigens to Mycobacterium tuberculosis in mice.

Exploiting fungal cell wall components in vaccines

Design, Synthesis and Anti-Tmv Activity of Novel Α-Aminophosphonate Derivatives Containing a Chalcone Moiety That Induce Resistance Against Plant Disease and Target the TMV Coat Protein.

Design, Synthesis, and Anti-Tobacco Mosaic Virus (TMV) Activity of Glycoconjugates of Phenanthroindolizidines Alkaloids

Synthesis and immunological evaluation of the unnatural β-linked mucin-1 Thomsen-Friedenreich conjugate

Plant-derived compounds: A potential source of drugs against Tobacco mosaic virus